Medquist enters into revolving credit facility for meeting working capital expenses

NewsGuard 100/100 Score

MedQuist Inc. (Nasdaq: MEDQ) today announced it has entered into a five-year $25 million revolving credit facility. The credit facility provides committed revolving funding through August 2014 and includes an option whereby the Company may increase its maximum credit up to $40 million, based on certain terms and conditions. The credit facility is a working capital facility that may be used for general corporate purposes. The Company does not currently anticipate borrowing under the credit facility.

Separately, the MedQuist Board of Directors, at a meeting held on August 27, 2009, unanimously declared a special cash dividend of $1.33 per share on MedQuist's common stock. The dividend will be paid on September 15, 2009 to shareholders of record as of the close of business on September 9, 2009. While the analysis of the tax impact of the dividend has not been completed, the Company expects a significant portion of the distribution will not be a taxable dividend for U.S. income tax purposes.

Robert Aquilina, Chairman of the Board, stated, "In declaring this special cash dividend, the Board considered the Company's financial position, earnings, earnings outlook, capital spending plans and other relevant factors. The Board continues to explore opportunities to enhance returns on shareholder equity."

Posted in:

Tags:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.